STALICLA is a mission-driven biotech company, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). We have developed a disruptive approach, the Databased Endophenotyping Patient Identification technology. Databased Endophenotyping Patient Identification uses big data analytics, to match the right treatment with the right ASD patients.
STALICLA is headquartered in Geneva, Switzerland.
The company has established a research partnership with the Greenwood Genetic Center, a leading research center for ASD based in South Carolina, USA.